deltatrials
Completed PHASE2/PHASE3 NCT00132561

A Trial of Intermittent Treatment in the Prevention of Malaria in Senegalese Children

A Double-blind, Randomised, Placebo-controlled Trial to Measure the Potential of Intermittent Treatment With Artesunate Plus Sulphadoxine/Pyrimethamine (SP) to Reduce the Malaria Burden in Sub-Saharan Africa

Sponsor: Cheikh Anta Diop University, Senegal

Conditions Malaria
Interventions Sulfadoxine/pyrimethamine and artesunate
Updated 6 times since 2017 Last updated: Jan 11, 2017 Started: Jun 30, 2002 Completion: Dec 31, 2003

This PHASE2/PHASE3 trial investigates Malaria and is currently completed. Cheikh Anta Diop University, Senegal leads this study, which shows 6 recorded versions since 2002 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2_PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2_PHASE3

    First recorded

Jun 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cheikh Anta Diop University, Senegal
  • Institut de Recherche pour le Developpement
  • Institut de Recherche pour le Developpement, Senegal
  • London School of Hygiene and Tropical Medicine
  • Ministry of Health, Senegal
Data source: London School of Hygiene and Tropical Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Dakar, Senegal